A carregar...
Publicação
Harnessing complex metabolic signatures to predict drug efficacy in ovarian cancer
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 7.72 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
"Ovarian carcinoma (OvC) is the most lethal gynecologic malignancy. Unfortunately, most cases are diagnosed at the later stages of the disease, impacting patient outcomes, resulting in a 5-year survival rate of less than 40%. The standard-of-care (SOC) treatment consists of cytoreduction surgery for tumor debulking and adjuvant chemotherapy, comprising a combination of platinum (cisplatin or carboplatin) with taxane (paclitaxel or docetaxel) agents.(...)"
Descrição
Palavras-chave
precision medicine ovarian cancer